Abstract:Objective To investigate the effects and mechanisms of LRIG1 overexpression on chemosensitivity of human bladder cancer T24 cell line to cisplatin.Methods Human bladder cancer T24 cell line was used in the experiment since December 2012.Firstly,human bladder cancer T24 cells which were capable of highly expressing exogenous LRIG1 gene were established and identified.The T24 cells were divided into 3 groups:experimental group (transfected with Ad-Surp-LRIGl),control group (transfected with Adeno-SP-EGFP),blank control group (untransfected).Secondly,experiments of CDDP-induced apoptosis were divided into 4 groups:control group (untreated),CDDP group (treated with CDDP),CDDP/Adeno-SP-EGFP group (treated with CDDP/Adeno-SP-EGFP and CDDP),CDDP/Ad-Surp-LRIG1 group (treated with CDDP/Ad-Surp-LRIG1 and CDDP).The expression of mRNA and protein of LRIG1 and EGFR were detected by RT-PCR and Western blot.The effect of LRIG1 and/or CDDP on the expression of EGFR and pEGFR of T24 cells were measured by Western blot.The cellular sensitivity to CDDP was evaluated by cell counting Kit-8 (CCK-8).The cells apoptosis rates were examined by flow cytometry.Results The mRNA expression of LRIG1 and EGFR in experimental group,control group and blank control group were (2.79±0.15) and (0.65±0.05),(0.76±0.09) and (1.98 ±0.07),(0.66±0.05) and (2.05 ± 0.04);the protein expression of LRIG1 and EGFR in experimental group,control group and blank control group were (1.98 ± 0.12) and (0.92 ± 0.05),(0.88 ± 0.07) and (2.51 ± 0.07),(1.00 ± 0.08) and (2.42 ± 0.09).The differences were significant between experimental group and the other groups (P ＜ 0.05),the difference was not significant between control group and blank control group (P ＞ 0.05).The IC50 values in CDDP group,CDDP/Adeno-SP-EGFP group and CDDP/Ad-Surp-LRIG1 group were (30.96 ± 0.57) μg/ml,(31.55 ± 0.48) μg/ml and (14.09 ± 0.31) μg/ml.The difference were significant between CDDP/Ad-Surp-LRIGl group and the other groups (P ＜ 0.05),the difference was not significant between CDDP group and CDDP/Adeno-SP-EGFP group(P ＞ 0.05).The apoptosis rate in CDDP/Ad-SurpLRIGl group [(69.77 ± 2.14)％] was significantly higher than that in CDDWAdeno-SP-EGFP group [(48.15±1.53)％],CDDP group [(46.82±1.23)％] and controlgroup [(3.17±0.21)％] (P＜ 0.01);the difference was not significant between CDDP group and CDDP/Adeno-SP-EGFP group (P ＞ 0.05).The expression of total EGFR protein and nuclear pEGFR protein in control group、CDDP group、CDDP/Adeno-SP-EGFP group,CDDP/Ad-Surp-LRIG1 group were (2.52 ± 0.11) and (1.76 ± 0.08),(1.22±0.05) and (2.75±0.15),(1.25 ±0.05) and (2.82±0.13),(0.32±0.02) and (1.08± 0.04).The differences between CDDP group and control group,CDDP/Adeno-SP-EGFP group and CDDP/ Ad-Surp-LRIGl group were significant (P ＜ 0.05),the difference was not significant between CDDP group and CDDP/Adeno-SP-EGFP(P ＞ 0.05).Conclusions LRIG1 promotes the cisplatin-induced apoptosis of T24 cells and enhances the sensitivity to cisplatin by down-regulating the expression of EGFR and pEGFR.

NDRG2 increases bladder cancer cell sensitivity to cisplatin by inhibiting Bcl-2 expression

Lentivirus-mediated NDRG2 gene overexpression inhibits radioresistance of bladder cancer cells

Knock-down of NDRG2 Sensitizes Cervical Cancer Hela Cells to Cisplatin Through Suppressing Bcl-2 Expression.

Overexpression of N-Myc Downstream-Regulated Gene 2 (NDRG2) Regulates the Proliferation and Invasion of Bladder Cancer Cells in Vitro and in Vivo

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer

N-myc Downstream Regulated Gene 1 Inhibition of Tumor Progression in Caco2 Cells.

NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells.

NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer

N-myc Downstream-Regulated Gene 1 Promotes Oxaliplatin-Triggered Apoptosis in Colorectal Cancer Cells Via Enhancing the Ubiquitination of Bcl-2

Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.

NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade

NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer

Ndrg2 Inhibits Hepatocellular Carcinoma Adhesion, Migration and Invasion by Regulating Cd24 Expression

Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion

CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.

Overexpression of LRIG1 gene enhances chemosensitvity of human bladder cancer T24 cell line to cisplatin

Effect of NDRG2 on proliferation of breast cancer cells

Up-Regulation Of Pvhl Along With Down-Regulation Of Hif-L Alpha By Ndrg2 Expression Attenuates Proliferation And Invasion In Renal Cancer Cells